Organization structure of Gsk
Download as PPTX, PDF9 likes24,170 views
GlaxoSmithKline is a global healthcare company formed in 2001 through the merger of Glaxo Wellcome and SmithKline Beecham. It researches, develops and markets pharmaceuticals, vaccines and consumer healthcare products. GSK operates in over 150 countries with 84 manufacturing sites worldwide. Its three core business areas are Pharmaceuticals, Vaccines, and Consumer Healthcare. GSK is focused on growing its diversified global business, delivering more products with value, and simplifying its operating model.
Organization structure of Gsk
- 2. HISTORY GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome group and SmithKline Beecham group, but their combined histories go back much further than that. Beginning with 1715: Plough Court Pharmacy was established 1830: John K Smith opened his first drugstore 1842: Beecham’s Pills brand was launched 2000: Planned merger of Glaxo Wellcome and SmithKline Beecham was announced
- 3. Mission : Do more, Feel Better, Live Longer. The business is focused around the delivery of three strategic priorities which aim to increase growth, reduce risk and improve the company’s long-term financial performance. These priorities are: • Grow a diversified global business, • Deliver more products of value, • Simplify the operating model.
- 4. What GSK does? GSK is a science-led global healthcare company. It researches and develops a broad range of innovative products in three primary areas viz., Pharmaceuticals, Vaccines and Consumer Healthcare. GSK has a significant global presence with commercial operations in more than 150 countries, a network of 84 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.
- 5. Pharmaceuticals GSK’s Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. It’s portfolio is made up of both patent- protected and off patent medicines. Such as, products for major disease areas like asthma, cancer, infections, mental health, diabetes and digestive conditions. £15.5bn turnover 67% of Group
- 6. Vaccines GSK’s Vaccines business is one of the largest in the world, producing paediatric and adult vaccines against a range of infectious diseases. In 2014, it distributed more than 800 million doses to 170 countries, of which over 80% were supplied to developing countries. £3.2bn turnover 14% of Group
- 7. Consumer Healthcare GSK’s Consumer Healthcare business develops and markets a range of products in the areas of: Pain Relief, Respiratory, Oral Health, Nutrition/Gastro Intestinal and Skin Health. These include a number of well-known global brands such as Sensodyne, Parodontax, Poligrip, Voltaren, Aquafresh toothpaste, Horlicks, Panadol, Breathe right nasal strips, Otrivin and Theraflu. £4.3bn turnover 19% of Group
- 9. Corporate Executive Team (CET) Sir Andrew Witty: GSK CEO & member of the Board &Corporate Executive Team Roger Connor: President, Global Manufacturing & Supply Simon Dingemans: Chief Financial Officer Nick Hirons: Senior Vice President, Global Ethics and Compliance Abbas Hussain: President, Global Pharmaceuticals David Redfern: Chief Strategy Officer Dr, Moncef Slaoui: Chairman, Global Vaccines Claire Thomas: Senior Vice President, Human Resources Phil Thomson: Senior Vice President, Communications and Government Affairs Don Troy: Senior Vice President & General Counsel Patrick Vallance: President, Pharmaceuticals R&D Emma Walmsley: CEO, GSK Consumer Healthcare
- 10. Board committees Audit And Risk Committee Remuneration Committee Nominations Committee Finance Committee Corporate Social Responsibility Committee Corporate Administration and Transactions Committee
- 11. Audit and risk Committee Members: Stacey Cartwright Lynn Elsenhans Sir Deryck Maughan Dr. Daniel Podolsky Secretary: Victoria Whyte In attendance: Chairman CEO, CFO,General Counsel Chairman, Global Vaccines Head of Audit & Assurance SVP, Global Ethics & Compliance Chief Medical Officer, Representative of external auditors, Financial Controller Frequency of meetings: Not less than four times a year The Audit & Risk Committee reviews: The integrity of financial and internal reporting process The integrity of financial statements The external and internal audit processes The system of internal controls and the identification and management of risks The committee also proposes to shareholders the appointment, re-appointment and removal of external auditors and is directly responsible for their remuneration and oversight of their work. Chair: Judy Lewent
- 12. Remuneration Committee Members: Dr Stephanie Burns Judy Lewent Sir Deryck Maughan Hans Wijers Secretary: Victoria Whyte In attendance: CEO, Head of Human Resources, Head of Reward, Committee adviser - Deloitte LLP, Any Non-Executive Director shall be entitled to attend the committee meetings. Frequency of meetings: Four times a year and otherwise as necessary. The Committee consists of Independent Non- Executive Directors and the Chairman The Chairman and the CEO are responsible for evaluating and making recommendations to the Board on the remuneration of Non-Executive Directors within the terms of the approved Remuneration Policy Chairman: Urs Rohner
- 13. Nominations Committee Members: Professor Sir Roy Anderson Sir Deryck Maughan Judy Lewent Lynn Elsenhans Secretary: Victoria Whyte In attendance: CEO, Head of Human Resources, External Advisers - as appropriate Frequency of meetings: The committee meets at least twice a year to consider succession planning, with other meetings held as required. The Nominations Committee reviews the structure, size and composition of the Board and the appointment of members to the Board and the CET. The committee also monitors the planning of succession to the Board and senior management. It is also responsible for considering and, if appropriate, authorising conflicts of interest. The committee consists of Independent Non-Executive Directors and the Chairman. Chairman: Sir Philip Hampton
- 14. Finance Committee Members: All directors Secretary: Victoria Whyte Frequency of meetings: Held as necessary. The Finance Committee reviews and approves the following on behalf of our Board: The annual report Form 20-F (for financial reporting in the US) The convening of the annual general meeting Preliminary and quarterly statements of trading results, dividends and major licensing and capital transactions Each director is a member of the committee and a meeting can comprise just three members but must include the company chairman, or the chairman of the audit & risk committee, and the CEO or CFO
- 15. CSR Committee Members: Dr Stephanie Burns Lynn Elsenhans Dr Daniel Podolsky Hans Wijers Secretary: Victoria Whyte In attendance: CEO, Head of Communications and Government Affairs, Head of Human Resources, General Counsel, Head of Corporate Responsibility and Reporting, Global Pharmaceuticals (President), Pharmaceutical R&D(President), Consumer Healthcare(President), Global Manufacturing & Supply(President), Independent External Corporate Responsibility Adviser Other executives are invited to attend the Committee as necessary Frequency of meetings: Four times a year or more frequently as necessary. The Corporate Responsibility Committee provides a Board-level forum for the review of external issues that could potentially impact upon our business and reputation. The Committee is also responsible for overseeing our worldwide charitable donations and community support. The Committee consists of Independent Non- Executive Directors and the Chairman. Chairman: Lynn Elsenhans
- 16. Corporate Administration and Transactions Committee Members: Directors, CET members and the Company Secretary Frequency of meetings: Held as necessary. The Corporate Administration and Transactions Committee reviews and approves matters in connection with the administration of the business, and of certain corporate transactions. The committee consists of the directors, Corporate Executive Team members and the Company Secretary.
- 17. Some Facts and Figures As of 2013 GSK had offices in over 115 countries and employed over 90,000 people, 12,500 in R&D. The company's single largest market is the United States. Its US headquarters are in The Navy Yard, Philadelphia, and Research Triangle Park, North Carolina; its consumer-products division is in Moon Township, Pennsylvania. Total No. of Employees (2015): 96,575 Net Income(2014): £2.831 billion As of 6 May 2015 it had a Market Capitalization of £73 billion, the fourth- largest of any company listed on the London Stock Exchange.
- 18. Key achievements We are the 1st pharmaceutical company to sign up to the AllTrials campaign for research transparency. We invested £3.1 billion in 2014 in our search to develop new medicines, vaccines and consumer products. Four new products approved in 2014 We have around 40 new molecular entities in phase II/III development. We have 84 manufacturing sites in 36 countries making our medicines, vaccines and consumer healthcare products. 4 billion albendazole tablets donated to eliminate two neglected tropical diseases since 1998. More than 13,000 people work in R&D in our search for new medicines, vaccines and consumer healthcare products. In 2014, we distributed more than 800 million doses of vaccines around the world. We employ around 98,000 people in over 100 countries, with more than a third of these in emerging markets. In March 2015 we acquired Novartis’s vaccines business (excluding influenza vaccines) and combined our Consumer Healthcare businesses to create a new company.
- 19. References: https://www.gsk.com/ https://en.wikipedia.org/wiki/GlaxoSmithKline www.google.com
- 20. Thankyou
Editor's Notes
- #3: 1715 Plough Court Pharmacy established Plough Court pharmacy is established, the forerunner of Allen and Hanburys, in London by Silvanus Bevan. The A&H name continues today. 1830 John K Smith opens his first drugstore 1830 John K Smith opens his first drugstore in Philadelphia. John's younger brother, George, joins him in 1841 to form John K Smith & Co. 1842 Beecham’s Pills brand launches Thomas Beecham launches the Beecham's Pills business in England. The laxative is to become widely successful. 1884 Burroughs Wellcome registers ‘Tabloid’ trademark ‘Tabloid’ is registered as a Burroughs Wellcome trademark to describe its compressed tablets. By 1898, the word was being used generally to describe a compressed or concentrated dose of anything. Hence the term ‘tabloid journalism’, which first appears in written records in 1901
- #4: Improving quality of human life by enabling people to do more, feel better and live longer. Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.
- #13: Within its terms of reference, and the approved Remuneration Policy, the Remuneration Committee determines the remuneration of the Executive Directors and members of the CET and, with the assistance of external independent advisors, evaluates and makes recommendations to our Board on remuneration policy.